Gastrointestinal Hemorrhage without CC/MCC DRG Reimbursement

DRG 379 addresses inpatient stays for gastrointestinal hemorrhage without a Major Complication or Comorbidity or Complication or Comorbidity, covering cases that require hospital management but lack higher-severity comorbid conditions. This classification matters for inpatient reimbursement because Medicare Diagnosis-Related Group payment is assigned by DRG and severity level, which determines the standardized prospective payment for these admissions.

DRG 379 Overview

DRG 379 covers inpatient admissions for patients with gastrointestinal bleeding that do not have a Major Complication or Comorbidity or a Complication or Comorbidity. This category captures cases where bleeding requires hospital evaluation and management but without higher-severity comorbid conditions that increase resource use. It matters for Medicare payment because lump-sum Diagnosis-Related Group reimbursement is based on assigned DRG severity and influences hospital reimbursement for these common acute admissions. Understanding this DRG helps clarify expected payment classification and resource implications for uncomplicated gastrointestinal hemorrhage cases.

Acute hemostatic intervention trials: randomized or pragmatic studies testing different endoscopic, interventional radiology, or pharmacologic strategies to achieve and sustain hemostasis in patients admitted with active upper or lower gastrointestinal bleeding without major comorbid complications. These trials typically enroll adults presenting to the emergency department or hospital with confirmed GI hemorrhage (e.g., peptic ulcer bleeding, diverticular bleed, angiodysplasia) and compare immediate procedural approaches, timing of endoscopy, or short-term adjunctive medications to reduce transfusion needs and rebleeding. Results are directly relevant to hospital clinicians and payers because they inform resource use during the index admission (length of stay, procedural utilization, transfusion frequency) and help define protocols that can reduce costly readmissions and complications.
Comparative effectiveness studies of risk stratification and care pathways: observational cohort studies or cluster-randomized evaluations that compare risk-scoring systems (such as adaptations of clinical severity scores), early discharge criteria, or standardized admission pathways (observation unit versus inpatient ward) for patients with non-severe GI hemorrhage without CC/MCC. These studies focus on patients who are hemodynamically stable or have limited transfusion requirements to determine which pathways safely minimize unnecessary inpatient days, diagnostic testing, and endoscopic timing. Findings are important for payers and hospitals aiming to allocate inpatient beds appropriately, lower avoidable costs, and maintain quality metrics by identifying which patients can be managed safely with less intensive inpatient resources.
Post-discharge outcomes and secondary prevention research: prospective cohort studies and pragmatic trials evaluating outpatient follow-up strategies, medication adherence programs, or secondary prevention interventions (for example, H. pylori eradication verification programs, anticoagulation management protocols, or surveillance planning) among survivors of GI hemorrhage without major complications. These investigations enroll discharged patients to measure rates of rebleeding, readmission, medication complications, and long-term functional outcomes, and to test interventions that reduce recurrence risk. This area matters to providers and payers because preventing recurrent bleeding and readmissions improves patient safety and lowers downstream costs associated with repeat hospitalizations and procedures.

Acute hemostatic intervention trials: randomized or pragmatic studies testing different endoscopic, interventional radiology, or pharmacologic strategies to achieve and sustain hemostasis in patients admitted with active upper or lower gastrointestinal bleeding without major comorbid complications. These trials typically enroll adults presenting to the emergency department or hospital with confirmed GI hemorrhage (e.g., peptic ulcer bleeding, diverticular bleed, angiodysplasia) and compare immediate procedural approaches, timing of endoscopy, or short-term adjunctive medications to reduce transfusion needs and rebleeding. Results are directly relevant to hospital clinicians and payers because they inform resource use during the index admission (length of stay, procedural utilization, transfusion frequency) and help define protocols that can reduce costly readmissions and complications.
Comparative effectiveness studies of risk stratification and care pathways: observational cohort studies or cluster-randomized evaluations that compare risk-scoring systems (such as adaptations of clinical severity scores), early discharge criteria, or standardized admission pathways (observation unit versus inpatient ward) for patients with non-severe GI hemorrhage without CC/MCC. These studies focus on patients who are hemodynamically stable or have limited transfusion requirements to determine which pathways safely minimize unnecessary inpatient days, diagnostic testing, and endoscopic timing. Findings are important for payers and hospitals aiming to allocate inpatient beds appropriately, lower avoidable costs, and maintain quality metrics by identifying which patients can be managed safely with less intensive inpatient resources.
Post-discharge outcomes and secondary prevention research: prospective cohort studies and pragmatic trials evaluating outpatient follow-up strategies, medication adherence programs, or secondary prevention interventions (for example, H. pylori eradication verification programs, anticoagulation management protocols, or surveillance planning) among survivors of GI hemorrhage without major complications. These investigations enroll discharged patients to measure rates of rebleeding, readmission, medication complications, and long-term functional outcomes, and to test interventions that reduce recurrence risk. This area matters to providers and payers because preventing recurrent bleeding and readmissions improves patient safety and lowers downstream costs associated with repeat hospitalizations and procedures.

OpenPayer

Summary & Overview

Gastrointestinal Hemorrhage without CC/MCC: Inpatient Reimbursement Overview

DRG 379 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes